<DOC>
	<DOCNO>NCT00393523</DOCNO>
	<brief_summary>To assess safety immunogenicity booster dose hepatitis B vaccine child receive 3-dose primary series either RECOMBIVAX HB ENGERIX-B . The primary vaccination series ( give 4 8 year prior study entry consist licensed hepatitis B vaccine product ( either RECOMBIVAX HB ENGERIX-B ) . The booster dose give study either investigational Merck product ( Modified Process Hepatitis B Vaccine ) license ENGERIX-B vaccine .</brief_summary>
	<brief_title>Hepatitis B Vaccine Booster Study ( V232-058 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy Children 4 8 year age Complete medical record document receive previous hepatitis B vaccination first year life ( Cohort A B ) Complete 3dose vaccination either primary series RECOMBIVAX HB primary series ENGERIXB ( Cohort A B ) Birth mother know carrier hepatitis B virus ( Cohort C ) History previous hepatitis B vaccine History vaccination hepatitis B vaccine ( Cohort C ) Known suspect hypersensitivity component RECOMBIVAX HB ENGERIXB ( eg aluminum , yeast ) recent administration hepatitis B immune globulin ( HBIg ) , serum immune globulin , bloodderived product Receipt investigational drug vaccine within 3 month prior study vaccine plan within study period Impairment immunologic function recent use immunomodulatory medication A Combination different hepatitis B vaccine use primary vaccination series ( Cohort A B )</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>